Background: Proxy decision makers often have to make decisions for people with advanced dementia. Their expectations regarding prescribed medications have the potential to influence prescription or withdrawal of medications. However, few studies to date have explored this. Aim: To explore proxy decision makers' expectations of prescribed medications for people with advanced dementia and to consider how these change with changing goals of care and dementia progression. Design: This is a qualitative semi-structured interview study. Setting/participants: In total, 15 proxy decision makers of people with advanced dementia were recruited via general practitioners (n = 9), Join Dementia Research (n = 3) and the Alzheimer's Society Northern Ireland (n = 3). Results: Five key themes emerged: the role as advocate, attitudes to medicines and medicine taking, uncertainty over the benefit of anti-dementia medications, stopping medications, and communication and decision-making. Proxy decision makers desired more information about prescribed medicines, particularly the indications, benefits and risks of treatment. Despite uncertainty about the benefits of anti-dementia medications, proxy decision makers were reluctant for these medications to be withdrawn. Reluctance to stop other prescribed medicines was also expressed but reduced with changing goals of care and dementia progression. Although some proxy decision makers expected to be involved in medication-related decisions, the majority preferred to delegate these decisions to healthcare professionals. However, they expected to be informed of any medication-related decisions made. Conclusion: Proxy decision makers vary in terms of their desire for active involvement in the medication decision-making process. Healthcare professionals should facilitate proxy decision maker involvement if desired. Further research is required to consider the impact of proxy decision maker involvement in decision-making.
• • Patients with advanced dementia often cannot participate in decision-making about their care; proxy decision makers (family members, friends or next of kin), therefore, make decisions on their behalf. • • Proxy decision maker expectations of medications have the potential to influence decisions to prescribe or withdraw medications. • • The few studies conducted to date which explore proxy decision makers' expectations of medications for patients with dementia consider all stages of disease and do not focus on the advanced stages of the condition. 1 Altnagelvin Area Hospital, Londonderry, UK 2 School of Pharmacy, Queen's University Belfast, Belfast, UK
What this paper adds?
• • This study is the first to explore and describe proxy decision makers' expectations of prescribed medications for people with advanced dementia and to consider how these expectations may change with changing goals of care and disease progression. • • Proxy decision makers felt that they had a key role in acting as an advocate and providing information to healthcare professionals for the person for whom they made decisions, particularly about any symptoms experienced. They reported an expectation for more information about prescribed medicines and specifically wanted details such as indications, benefits and risks of treatment. Although some expected to be involved in medication-related decisions, the majority preferred to delegate these decisions to healthcare professionals. However, they expected to be informed of any medication-related decisions made. • • Despite uncertainty about the benefits of anti-dementia medications, proxy decision makers were reluctant for these medications to be withdrawn. Reluctance to stop other prescribed medicines was also expressed, due to fear of potential consequences. However, this reluctance reduced as proxy decision makers considered changing goals of care and dementia progression.
Implications for practice, theory or policy
• • Communication between health-care professionals and proxy decision makers regarding prescribed medications (indications, risks and benefits) is of critical importance. •
Introduction
Dementia is a progressive, chronic, incurable neurodegenerative condition in which widespread neuronal cell death results in multiple deficits across cognitive domains including memory, behaviour, language, movement and executive function and ability to recognise familiar people or common objects. 1, 2 Disease progression is characterised by cognitive and physical decline which can adversely impact on ability to conduct basic and instrumental activities of daily living, [3] [4] [5] accompanied by an increasing dependence on others for care. [6] [7] [8] Stage 7 of the Functional Assessment Staging Test (FAST; ranging from 7A to 7F, with 7F indicating the most severe dementia) provides a useful description of the features of advanced dementia including profound memory deficits, minimal verbal abilities, inability to ambulate independently, inability to perform any activities of daily living, urinary and faecal incontinence, inability to sit up without assistance and loss of the ability to smile in the very late stages. 9 Patients with advanced dementia often cannot participate in decisionmaking about their care. 10 Consequently, decisions are made by proxy decision makers: family members, friends and next of kin who act in their best interest. [11] [12] [13] [14] [15] People with dementia and their caregivers hold high expectations for new medications, 16 which may be unrealistic, leading to disappointment and dissatisfaction with care. 17 Managing the expectations of proxy decision makers is an important aspect of treatment in advanced dementia, 18 as they have the potential to influence the prescription or withdrawal of medications in this vulnerable patient group. [19] [20] [21] [22] [23] However, despite the importance of expectations in shaping the decision-making process, [24] [25] [26] few studies have explored proxy decision makers' expectations of medications in advanced dementia; studies considering all stages of disease have reported that anti-dementia medicines (acetylcholinesterase inhibitors (AChEIs) including donepezil, galantamine and rivastigmine, which inhibit breakdown of acetylcholine, an important neurotransmitter for memory) gave people hope, 20, [27] [28] [29] and, despite lack of clarity about their benefits, were 'worth a try', 30 with fears about deterioration if these medications were stopped. 27 This study aimed to contribute to the limited evidence base.
Aim
To explore proxy decision makers' expectations of prescribed medications for people with advanced dementia. The following objectives were identified: 
Methods

Setting/participants
Proxy decision makers of people with advanced dementia in a region of the United Kingdom (Northern Ireland (NI)) were recruited. A proxy decision maker was defined as an adult family member or friend in regular contact (on at least one occasion per week) with the person with advanced dementia, who was their next of kin, or made decisions about the care of that person in conjunction with healthcare professionals. Further inclusion criteria were as follows:
• • FAST score of between 7A and 7F for the patient's cognitive function, indicating severe/advanced dementia. 9 Proxy decision makers completed this instrument as a proxy measure of function. • • Superficial knowledge of medication(s) prescribed (names and broad purpose).
Sampling and recruitment
Purposive sampling was undertaken to identify proxy decision makers of people with advanced dementia. 
Study design and data collection
Face-to-face, semi-structured interviews were conducted by B.McC. (a postgraduate researcher and qualified pharmacist) in proxy decision makers' homes using an interview schedule (Table 1) to facilitate sensitive, flexible, in-depth exploration of individuals' views within an overarching structure by which commonalities of experience could be identified. 31 Interview questions were developed following literature review and discussions within the research team and refined based on feedback from piloting. No prior relationships existed between participants and the researcher before study commencement. Participants were aware that the researcher was a postgraduate student from the School of Pharmacy, Queen's University Belfast. Participants provided written informed consent. Recruitment continued until analysis revealed no further novel themes emerging.
Data analysis and validation
Data collection was undertaken between March 2016 and May 2016. Interviews were digitally audio-recorded and transcribed verbatim. Transcripts were anonymised using 6. How did you feel when you were told that X would start dementia medications? 7. What information were you given? Who gave it to you? How did you feel about the information you were given? (a) Were you given any information about when X might have to stop taking their dementia medications? 8. What do you think this/these medicine(s) is/are doing for X? Why do you think that? 9. What do you hope this/these medicine(s) will do for X in the longer term? Proxy decision makers' experiences and views on decision-making regarding medicine use 10. Have you ever had any discussions with the doctor or any other healthcare professional about having medicines started or stopped for X? (a) Can you tell me more about this? 11. What are your views on being involved in making decisions about X's medicines as his/her condition gets worse or if the doctor tells you that X has only a few weeks left to live? Opinions on the withdrawal of prescribed medicines from people with dementia as goals of care change and dementia progresses 12. In the future, if X's dementia was getting more severe how would you feel if this/ these medicine(s) was/were to be stopped? 13. In your view, what are the key things you need to be aware of when making decisions about X's medications? a unique code comprising "PDM" (proxy decision maker) and a number to reflect the sequence in which participants were interviewed.
Interviews were conducted and analysed by a female pharmacist of Irish descent (B.McC.), who had undertaken training in qualitative research methods. Data analysis was iterative, with simultaneous data collection and analysis leading to alterations in the interview schedule in line with emerging themes. 32 The framework method of analysis developed by Ritchie and Spencer 33 was applied to the data generated. Microsoft Word was used to aid with data management. Validation of analysis was performed (C.P., B.McC.), and consensus reached on the final themes.
Results
In total, 20 of 35 proxy decision makers (57.1%) approached expressed interest in the study. Fifteen (42.9%) met the inclusion criteria and agreed to take part; of these, 9 were recruited via GPs, 3 via JDR and 3 via the Alzheimer's Society, NI. Interviews lasted an average of 37.5 min (range: 24-60 min). Demographic characteristics of participants are detailed in Table 2 .
Five key themes emerged from the interviews: (1) the role of the proxy decision maker as advocate, (2) attitudes to medicines and medicine taking, (3) uncertainty over the benefit of anti-dementia medicines, (4) stopping medications and (5) communication and decision-making.
The role of the proxy decision maker as advocate
Proxy decision makers reported that they knew the person with advanced dementia better than anyone else, including healthcare professionals. As a result, they felt they had a critical role in interpreting their symptoms: Proxy decision makers expected medications to be prescribed for control and/or relief of symptoms and comfort, particularly towards the end of life. They advocated for prescription of medications in some instances and in other cases requested withdrawal:
As she approaches the end of life she would need to get the medications that make her comfortable, that is really important for me … mummy doesn't have a voice, she has dementia, I am her voice, so it is my responsibility that she gets all the medicines that she needs. (PDM3) He is a diabetic as well … and they started him on a drug called metformin but he got severe diarrhoea with that and I requested that it be stopped. I mean I would rather him have slightly high blood sugar levels rather than diarrhoea because diarrhoea is much more upsetting for him and me also … in the future as he approaches the end of life, I don't think he will really need the tablet now because he won't be able to eat as much … (PDM10) Proxy decision makers placed hope in certain medications and as a result expected to see improvements in their loved one's condition. However, the side effects of some medications, for example, antipsychotics, mitigated against this hopefulness. In such cases, proxy decision makers were keen for medications to be reviewed:
I expected that this drug [risperidone] would make things better for her, you know, that she wouldn't be as scared but I was disappointed and scared myself as it left her so drowsy and out of it. I mean I couldn't even enjoy my visit to the 
Attitudes to medicines and medicines taking
Proxy decision makers highlighted the difficulties associated with trying to administer medications:
Getting them [medicines] down is the problem … the one in the morning goes into the porridge but it has to be crushed … but she doesn't eat all of the porridge, so I have no way of knowing how much of the medication [my sister] is actually taking, and that could be so dangerous for her … (PDM12)
When swallowing became problematic, proxy decision makers expected a medication review to determine whether the number of medicines could be reduced and to ensure that all medications were prescribed with a clear and current rationale:
[My wife] has to take ten different tablets each morning and night … it is a constant struggle for me and a real worry because she has such a poor swallow … it has been a while since her tablets have been reviewed and I think now that her swallow is so bad, now would be a good time to do it again … I would be relieved if she had to take less medicines. (PDM13)
Proxy decision makers required more information about the person's prescribed medications, emphasising the importance of having an appreciation of how medications work and what to expect in relation to benefits and adverse effects. Some held the belief that it was their responsibility to seek such information:
No one gives me any information about the tablets, that is for me to do myself on the Internet. (PDM1)
Others expected details to be provided by the prescribing physician, GP or pharmacist. However, in some cases, it was apparent that this information was not provided:
I expect the doctor [GP] maybe to tell me that level of detail [how the medications work] and to be honest they don't always provide it … if you had a pharmacist to tell you in a common sense kind of way, the important points about medications … (PDM11) Proxy decision makers also discussed specific medications and drug classes. Cardiovascular medications, including β-adrenoreceptor blocking drugs, anticoagulants, statins and angiotensin-converting enzyme inhibitors, were considered essential; proxy decision makers believed that these would prevent major cardiovascular events such as myocardial infarction and stroke:
The statin she needs because her cholesterol is so high, my expectation of it is that it will prevent further heart attacks and strokes from happening, so it is really important that she takes this tablet. (PDM3)
Uncertainty over the benefit of anti-dementia medicines
Proxy decision makers appeared uncertain over the benefits of AChEIs and memantine, with many reporting no perceived advantages: Others were unsure about the effect of these medications because they had no way of telling what their loved one would be like if they were not taking it:
The consultant told me that memantine would slow the dementia down … it is difficult to say whether it has slowed it down or not because I can't tell what the dementia would be like if he wasn't taking it, you know. (PDM5)
Stopping medicines
Opinions varied regarding stopping anti-dementia medications and other prescribed medications, as detailed below.
Anti-dementia medications. Some proxy decision makers were reluctant for these medications to be stopped due to concerns that this could cause deterioration in their loved one's condition: I wouldn't want to stop them [donepezil and memantine] because I would be afraid of what would happen if she stopped them, so we are just happy for her to continue to take them until whatever time she passes. (PDM11) Interestingly, others felt that such medications were making their loved one's condition worse and conveyed a sense of relief when these medications were stopped:
I was quite happy to get her off them [donepezil and memantine], because she is well advanced in her Alzheimer's and I don't see any sense in her being comatosed more [sic], because I do think the tablets comatosed [sic] her. To calm her down I think they really made her more dysfunctional rather than anything else. (PDM9)
Other prescribed medications. While some proxy decision makers felt that a review was necessary to reduce the number of prescribed medications, others were reluctant for medications to be stopped, citing concerns over potential consequences. However, as their loved one's condition began to deteriorate, many felt that some medications no longer had a role to play:
If you took it away [temazepam] I don't know if it would make an awful lot of difference given how much she sleeps anyway, I mean she basically sleeps for the same amount of time as she is awake during the day now. Essentially I think it is just, I think it is part of coming to the end of life and closing down. (PDM11)
We wouldn't protest, if anything, with [my wife], she is not going to get better, I know she is going to get worse. Sometimes I do think that the donepezil is there just because she has dementia, I mean her dementia is so advanced now I wonder is there even any point in her taking it at this stage? (PDM14)
Communication and decision-making
Some proxy decision makers explained that they found making medication-related decisions extremely difficult: Proxy decision makers expected any changes in medications to be communicated to them, particularly when medications were stopped:
I expect more in the way of communication from healthcare professionals … I mean I expect to be told when there are any changes to my mum's medicines … I believe the reasoning behind why they would be taking her off drugs to be very important to me … (PDM3)
The majority felt that healthcare professionals were equipped with the knowledge and expertise about medications to enable appropriate treatment decisions. Many felt that they did not possess the knowledge to make such decisions themselves. Some explained how they trusted their healthcare professional to make prescribing decisions, and they did not see it as their right to challenge those decisions:
I wouldn't be in a position to challenge them but I appreciate their courtesy at least for keeping me in the picture … I have full trust in my doctor, I don't know anything about the medicines or how they work on the body, they are the experts and so I just let them do their job. (PDM13) However, despite this trust, proxy decision makers wished to be kept informed of the decisions made about their loved one's medications. Conversely, some proxy decision makers desired greater involvement and a more active role in the decision-making process:
I just think that doctors and healthcare professionals need to be involving family a little bit more than they do … I know in the care home they say that the medications are reviewed annually with the GP but we are never involved in that. They never pick up the phone and say, 'The GP is coming to review the medications would you like to be here, or do you want to know the outcome of that?' If I don't actively go and ask can I have a look at my granny's medication list to see what has been added or discontinued, nobody would ever tell me. (PDM2)
Discussion
Main findings of the study
Proxy decision makers felt that it was their role to advocate for the person with advanced dementia. They expected healthcare professionals to ask about symptoms, prescribe medications to treat those symptoms and ensure comfort. The care of people with dementia towards the end of life is often less than optimal, [34] [35] [36] [37] [38] and there is a need for highquality palliative care for patients with dementia, with palliation of symptoms leading to improved comfort and quality of life. [39] [40] [41] [42] [43] Proxy decision makers in this study expected prescribed medications to be reviewed as swallowing difficulties manifested and dementia progressed, as reported by others. 44 Similar to this study, the taking of medications in advanced illness has previously been described as a 'daily struggle' by some caregivers. 45 Proxy decision makers viewed cardiovascular medicines as essential to prevent major cardiovascular events. However, studies which have examined medication appropriateness in dementia using expert consensus panels have categorised β-adrenoreceptor blocking drugs as 'sometimes appropriate', statins as 'never appropriate' in advanced dementia, 46, 47 anticoagulants as 'rarely appropriate' 46 or 'never appropriate' 47 and angiotensin-converting-enzyme inhibitors as 'sometimes appropriate' 46 or 'never appropriate'. 47 The recently developed Medication Appropriateness Tool for Co-morbid Health conditions in Dementia (MATCH-D) criteria also suggest that antihypertensive agents; lipid-lowering medications; and anti-platelet, anticoagulant and anti-thrombotic agents should be ceased in late-stage dementia. 48 Despite these recommendations, patients with advanced dementia often continue to receive medications of questionable benefit. [49] [50] [51] [52] Proxy decision makers' opinions of these medications may help to explain why they continue to be prescribed in advanced disease.
Many proxy decision makers in this study felt that they lacked information or access to a reliable source of information about medications prescribed for the person with advanced dementia. Some thought that it was their responsibility to actively seek such information and accessed the Internet to search for details pertaining to prescribed medications. Healthcare professionals should acknowledge the Internet as an information source about prescribed medications, be prepared to offer suggestions for appropriate Internet health resources and assist in evaluating the quality of the information obtained.
Some proxy decision makers articulated uncertainty about the benefits of anti-dementia medications because they had no way of measuring their effects, a finding also reported by others. 53 Despite this, there was reluctance for these medications to be stopped due to fear that withdrawal could accelerate disease progression or lead to the reintroduction of anxiety, aggression and challenging behaviours. A qualitative study focusing on AChEIs considered the views of caregivers of people with mild-to-advanced dementia. 27 Similar to this study, carers expected that withdrawal would hasten disease progression. Other studies have suggested that discontinuation of anti-dementia medications may worsen the chronic disease, particularly in those who initially respond to treatment, [54] [55] [56] [57] and there have been reports of abrupt decline in cognitive or functional abilities in patients or emerging challenging behaviours on discontinuation. Conversely, others suggest that AChEI discontinuation is safe and well tolerated in the majority of institutionalised patients. 58 Further studies are required to evaluate the effects of anti-dementia medication discontinuation, adding to the limited evidence base for patients with advanced dementia.
Proxy decision makers in this study expressed reluctance over stopping other prescribed medications, which reduced as the condition of their loved one deteriorated and as end of life approached. This reflects previous work which reported that caregivers could foresee a time when the symptoms associated with memory loss or with another illness might become so severe that taking a medication to treat memory loss was no longer desirable. 59 Similar to the study by Caron et al., 60 proxy decision makers expected changes to medications to be communicated to them. Medication management has been defined as one of many domains of care provided by caregivers 61 and includes roles such as administering multiple medications; avoiding medication errors and possible drug interactions; looking for side effects; making judgements regarding when to withhold, increase, decrease or discontinue a medication; and trying to make informed decisions about their medication management role by communication with healthcare providers. 62, 63 These roles are often made more difficult by unhelpful structures and practices in different healthcare settings. For example, changes to prescribed medications may not be communicated to caregivers if they were not present during the consultation. 64 The importance of improving communication between healthcare professionals and caregivers in end-of-life care settings and for those dying with dementia has been acknowledged. 65, 66 Recent work has identified the potential application of the MATCH-D criteria as a discussion aid or educational tool to facilitate this communication. 67 The revised Patients' Attitudes towards Deprescribing (rPATD) questionnaire also shows promise as a tool to supplement and guide communication about stopping medications and to highlight proxy decision maker beliefs and attitudes towards deprescribing. 68 Caregivers find decisions around end-of-life care very difficult. In situations where the wishes of the patient are not known in advance, they are helped by knowing the views held by the person with dementia before losing capacity. 13 Communication between proxy decision makers and healthcare professionals is vital to explore and understand the patient's previously stated goals and values, which should then guide and facilitate treatment decisions. Dementia-specific advance directives, which address change in cognition and goals of care as dementia progresses and are completed by patients before dementia occurs, would provide proxy decision makers with even greater reassurance that the treatment they choose is guided by what the patient would have wanted. 69 Proxy decision makers varied in their need to be actively involved in medication-related decisions. The majority were happy to delegate to, and placed substantial trust in, healthcare professionals; they did not feel that they had the appropriate medical knowledge to make such decisions, a finding reported by others. 60 The integral role of the physician in this regard has emerged in previous studies. 23, 43, 60, 70 In all cases, being informed of decisions made was essential for reassurance about the care received and to meet the expectation concerned with the proxy decision maker's own sense of involvement in such care.
Limitations of the study
Limitations must be acknowledged and considered when interpreting the data. This study recruited a sample from a very specific population of proxy decision makers for people with advanced dementia in one region of the United Kingdom (NI); as a result, there is the potential for sampling bias. 71 Selection bias may be present as proxy decision makers with no understanding of their loved one's medications were not recruited. One approach suggested to address this problem is through the generation of a larger sample size. 72 However, as this study reached data saturation, this was not considered necessary. 32, 71 
Implications for research
In this study, proxy decision makers of people with advanced dementia advocated for medicines to be prescribed to ensure their loved one's comfort, especially towards the end of life. Future research should explore the extent to which proxy decision makers' expectations are met in relation to ensuring comfort as end of life approaches, and their role in the decision-making process regarding initiation, continuation or withdrawal of medications. Further understanding of and insight into communication between healthcare professionals and proxy decision makers and the complexity of the healthcare professional-proxy decision maker relationship are critical in the development of an intervention or best-practice model that will serve to facilitate decision-making processes for people with advanced dementia.
What this study adds
This study is the first to explore proxy decision makers' expectations of prescribed medications in advanced dementia and to consider how these may change with changing goals of care and disease progression. Communication between healthcare professionals and proxy decision makers regarding prescribed medications is of critical importance. Healthcare professionals should facilitate proxy decision maker involvement in the medication decision-making process if desired.
Conclusion
Proxy decision makers described their role as advocate and providing information to healthcare professionals, particularly about symptoms experienced. They reported an expectation for more information about prescribed medicines, specifically regarding indications, benefits and risks of treatment. Proxy decision makers expressed reluctance at stopping prescribed medicines due to fear of potential consequences. However, this appeared to reduce with changing goals of care and dementia progression. Although some expected to be involved in medicationrelated decisions, the majority preferred to delegate these decisions to healthcare professionals. However, they expected to be informed of any decisions made. Further work is required to identify the impact of proxy decision makers' expectations for prescribed medications on prescribing for people with advanced dementia approaching the end of life.
